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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease
worldwide. The renal phenotype is characterized by progressive cystic enlargement of the kidneys leading to a decline in
renal function, hypertension and often end-stage renal disease (ESRD). Supportive care with blood pressure control and
management of pain, urinary infections and renal stone disease has, until recently, been the mainstay of treatment. With
the recent approval of tolvaptan for use in ADPKD, the disease progression may now be targeted specifically. Algorithms
that guide treatment initiation have been proposed but a more pragmatic and patient-individualized approach is often
needed to make decisions regarding therapy. It is highly important to identify ADPKD patients with rapidly progressive
disease who are likely to benefit most from this treatment and avoid treatment in patients that are unlikely to reach ESRD.
Methods and Results: Here we present a series of cases of ADPKD patients in whom therapy with tolvaptan has been
considered and report the rationale for the treatment decisions based on available lifestyle, clinical, biochemical,
radiological and genetic data.
Conclusions: These cases provide a discussion for the use of tolvaptan in ADPKD within the nephrology clinic and allow
insights into the practicalities of using this therapy outside of clinical trials.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is an
inherited disorder that predominantly affects the kidneys, but
also frequently causes abnormalities in other organs, such as
the liver and the pancreas, and the cerebral vasculature [1, 2].
The hallmark of ADPKD is continuous development of renal
cysts accompanied by an increase in total kidney volume (TKV),
hypertension and a reduction in glomerular filtration rate, cul-
minating in end-stage renal disease (ESRD) in the majority of
patients [1, 3, 4]. ADPKD is the most common inherited renal
disorder in adults; it accounts for 10% of ESRD cases [5], and
dialysis-dependent kidney failure develops in >50% of patients
by 60 years of age [6]. The prevalence of ADPKD is often stated
to be between 1 in 400 and 1 in 1000 live births [1]. However,
these numbers reflect the finding of cystic kidneys in autopsy
Received: April 3, 2017. Editorial decision: June 7, 2017
VC The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
62
Clinical Kidney Journal, 2018, vol. 11, no. 1, 62–69
doi: 10.1093/ckj/sfx071
Advance Access Publication Date: 27 July 2017
Original Article
Downloaded from https://academic.oup.com/ckj/article-abstract/11/1/62/4049583
by University of Newcastle user
on 18 May 2018
studies or a general lifetime risk of ADPKD rather than point
prevalence in a population [7]. A recent analysis of both
population-based studies and registries revealed a point preva-
lence for ADPKD of 3–5/10 000 individuals [8]. ADPKD usually
presents clinically in the third or fourth decade of life and is
associated with a range of symptoms, including pain in the
abdomen, flank or back, abdominal fullness, cyst haemorrhage,
nephrolithiasis, cyst infection, haematuria and hypertension [1,
9, 10]. Screening programmes, usually based on renal ultra-
sound scanning (USS), allow early detection of ADPKD in
patients with a positive family history [11, 12]. It is worth noting
that using renal USS to exclude ADPKD where there is a family
history of disease requires imaging up to the age of 40 years [11].
ADPKD follows an autosomal-dominant inheritance, resulting
in a positive family history in the vast majority of patients, with
individuals affected in every generation. However, spontaneous
mutations do also occur and account for 5% of cases [2]. ADPKD
is a consequence of mutations in two genes, PKD1 and PKD2,
which encode polycystin (PC)-1 and -2, respectively [2]. Mutations
in PKD1 are more common than in PKD2, accounting for 85% and
15% of cases, respectively [13]. Patients with ADPKD resulting
from PKD1 mutations show faster progression of disease with
more rapid cyst growth and loss of renal function [14, 15]. Both
PC-1 and PC-2 localize to the primary cilium—a finding that is in
line with cystic kidney diseases in general being regarded as so-
called ciliopathies [16]. Mutations in either PKD1 or PKD2 lead to
the perturbation of numerous intracellular signalling pathways,
resulting in increased secretion and proliferation of renal epithe-
lial cells [1]. One of the most consistent and thus probably pivotal
findings is an increase seen in the levels of the secondary mes-
senger cAMP whilst intracellular calcium levels are reduced [1].
Care of ADPKD patients was, until recently, limited to sup-
portive measures, due to the lack of targeted therapeutic strat-
egies. Consequently, nephrologists could only offer limited
strategies regarding disease progression and treatment mainly
focussed on symptoms and complications of ADPKD, including
blood pressure and pain control, in addition to antibiotic treat-
ment of cyst infections and treatment of renal stones; however,
therapy for the disease itself was not available [1, 17]. One of the
key strategies to slow down disease progression is the reduction
of intracellular cAMP levels, which, in rodent models, can be
achieved efficiently by blocking vasopressin receptor signalling
[18]. In 2012, tolvaptan, a potent, highly selective, orally available,
V2 receptor antagonist [19], was proven to significantly reduce
both kidney growth and loss of estimated glomerular filtration
rate (eGFR) in the 3-year randomized double-blinded placebo-
controlled TEMPO 3:4 trial, which enrolled 1445 ADPKD patients
from 129 sites [20]. Consequently, in 2015 tolvaptan was approved
by the European Medicines Agency (EMA) for the treatment of
adult patients with ADPKD in chronic kidney disease (CKD) stages
1–3 at treatment initiation with evidence of rapid disease progres-
sion [21]. However, use of tolvaptan is partly different in
European countries due to national regulations. As an example,
whilst in Germany the therapy is reimbursed for all patients that
fulfil the indication as formulated by the EMA, in England, reim-
bursement is reserved for CKD stages 2 and 3, as use of tolvaptan
for CKD stage 1 was not deemed cost-effective in a review by
NICE [22]. As the first approved targeted treatment of ADPKD, V2
receptor blockade is an urgently awaited advance for both ADPKD
patients and their physicians. However, a major new challenge is
the selection of ADPKD patients who will benefit from this treat-
ment, which is largely based on evidence of rapid progression.
The current consensus, as well as the approval criteria of the
EMA, is that patients in whom tolvaptan is initiated should
have evidence of rapid progression; however, it should be
remembered that the inclusion criteria in TEMPO 3:4 study that
documented the effect of tolvaptan did not require explicit evi-
dence of rapid progression (although by kidney size the
included patients were likely to be so). Thus, there is some dis-
crepancy between the clinical indications for tolvaptan use and
inclusion criteria used in recent clinical trials adding to the
complexity of selecting the appropriate patients for treatment.
In general, only patients with a high risk of reaching ESRD
are suitable candidates for tolvaptan treatment. Treatment
algorithms have been published that allow physicians to follow
expert guidance and look for evidence of disease progression in
order to inform treatment decisions, but the real-world scenar-
ios insist that a more practical and realistic approach must be
adopted in some cases.
Quantifying rapid progression
When considering rapid progression in ADPKD patients, the cri-
teria that provide direct evidence of rapid progression (Table 1)
can be separated from those that serve as predictors of future
progression (Table 2). Documenting the slope of eGFR is both
the easiest and most powerful indicator of disease progression
and is the first step in the algorithm provided by the ERA-EDTA
Working Groups on Inherited Kidney Disorders and European
Renal Best Practice (Figure 1). When judging eGFR loss, it is cru-
cial that potential causes of renal function loss other than
ADPKD are excluded. Conversely, when taking into account the
variability of creatinine values, a sufficient number of measure-
ments should be available. A decrease of 5 mL/min/1.73m2 in 1
year or 2.5 mL/min/1.73m2 per year over 5 years has been sug-
gested as a cut-off point for defining rapid progression [24].
Where this evidence is lacking, consideration of markers of risk
of progression can help treatment decisions to be made.
Younger patients in CKD stage 1 cannot be judged solely based
on eGFR loss, whereas CKD stage 1 in a patient >50 years of age
would exclude rapidly progressive disease. Whilst eGFR in
ADPKD patients may be maintained at a stable range for deca-
des through glomerular hyperfiltration [3], the disease pro-
gresses, as evidenced by the continuous increase in TKV
[20, 35]. Repetitive measurements of TKV could consequently be
used to measure the speed of kidney growth; this has shown
efficacy in clinical trials, with magnetic resonance imaging
(MRI)-based stereology and manual planimetry used to accu-
rately quantify kidney volume [4, 27, 36] (Figure 2). However, in
our experience, this strategy is impeded by the lack of access to
repetitive MRI volumetry and the variation in volume between
measurements in the practical setting.
Data from the Consortium for Radiologic Imaging Studies of
Polycystic Kidney Disease (CRISP) cohort has provided good evi-
dence that a large, height-adjusted TKV (htTKV), as measured
by MRI-based volumetry or USS-guided kidney length
(>16.5 cm), is a strong indicator of a patient reaching CKD stage
3 within 8 years [28, 29, 37]. When using a single measure of
Table 1. Direct evidence of rapid disease progression in ADPKD
Parameters
Rate of GFR decline
Decrease in eGFR of 5 mL/min/1.73m2 in 1 year [23]
Decrease in eGFR of2.5 mL/min/1.73m2 per year over 5 years [24, 25]
Rate of kidney growth
An annual increase in TKV of 5% per year [24, 25] with MRI as the
recommended imaging modality [24]
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TKV as an indicator of disease progression, it is important to
take patient height (as achieved by using htTKV) and age into
account due to continuous kidney growth in ADPKD. The Mayo
classification that was established by Irazabal et al. incorporates
these parameters into an efficient model predicting future eGFR
loss [30]. It is important to note that the calculator is not valid
for ‘atypical’ patients, which includes ADPKD kidneys where
there is asymmetrical, unilateral or segmental cystic change
[30]. Mayo classes 1C–E are associated with rapid progression
and patients in these classes are predicted to lose eGFR at a
speed of >2.4 mL/min/1.73 m2 per year. Importantly, this model
demonstrated that complicated protocols of volumetry, that
would not be available in most centres, are not required for clin-
ical decision-making (in contrast to clinical trials), as measuring
TKV using the ellipsoid equation showed a good correlation
with stereology measurements [30].
Cornec-Le Gall et al. identified other clinical and genetic factors
associated with rapid progression using data from the French
Genkyst cohort, including male sex, early occurrence of urological
complications or hypertension, and type of PKD mutation. These
factors were used to establish the PROPKD score, which classifies
patients according to their risk of progression to ESRD (with a
score >6 indicating rapid progression) [31]. Even though the
PROPKD score is a potentially useful tool, its use in clinical practice
has been hampered by the limited availability of genetic data for
the vast majority of ADPKD patients. In the event that the score
cannot be calculated for this reason, the features integrated in the
score (sex, urological complications and hypertension) should still
be considered when assessing ADPKD patients [31]. However, a
PROPKD score cannot be used in the absence of genetic data.
Despite intra-familial variance in disease progression, a detailed
family history documenting the age of ESRD in affected members
(especially if <55 years) is informative in terms of risk prediction
and would prompt imaging and genetic studies to allow an
informed decision regarding treatment to be made [25, 38].
The important challenge is now to implement a strategy
that allows for usage of the factors described in clinical practice
to select patients as candidates for the initiation of tolvaptan
treatment. The ERA-EDTA Working Groups on Inherited Kidney
Disorders and European Renal Best Practice (Figure 1) as well as
the UK Renal Association have proposed algorithms that can be
used to guide this decision and patient counselling [24, 25]. It is
important, however, that each patient is considered in an
individualized manner using all data on indicators of rapid pro-
gression, since no available algorithm will address all aspects of
progression. Therapy has to be considered and discussed with
all patients that fulfil the criteria of the EMA approval of tolvap-
tan, even if they do not meet all requirements of proposed deci-
sion algorithms. In general, comprehensive patient counselling
on efficacy and side effects of the therapy as well as individual
characteristics that indicate the expected degree of benefit are
central in order to come to an informed decision. Furthermore,
aspects other than rapid progression have to be taken into
account when giving advice to patients, such as comorbidities
and lifestyle (which may make taking a drug that increases
urine volume to 4–6 L impossible), as well as the contraindica-
tions for tolvaptan treatment and potential drug interactions.
The characteristics of patients enrolled in the TEMPO 3:4 study
should also be considered, as all patients were 50 years of age
with only very few patients being in CKD stage 3b (n¼ 39, 24 of
whom were in the tolvaptan treatment group) [39].
Here, we present five case studies of patients with ADPKD
who were considered for treatment with tolvaptan. We examine
how the criteria of rapid progression were incorporated with
other data on the patients’ history, to come to a decision, which
takes into account available evidence and also realistic consid-
erations regarding the initiation of tolvaptan. Patients reported
here provided verbal and written informed consent.
Results
Clinical case histories from five individuals diagnosed with
ADPKD are described. The cases involve patients with a broad
age range of 19–65 years. In deciding whether to initiate tolvap-
tan therapy in these patients, a number of factors were taken
into consideration, including: the patient’s clinical history, their
Table 2. Indirect evidence/predictors of rapid disease progression in ADPKD
Parameters Key indication/prediction
Genetics Truncating PKD1 mutations are associated with more rapid progression than non-truncating PKD1 mutations
[26]
PKD2 mutations are associated with the slowest progression [27]
Kidney size/Mayo
classification
Kidney length >16.5 cm by ultrasound may indicate risk of progression [28], but also consider patient age
htTKV>600 mL/m indicates rapid progression [29]
Mayo classification allows for prediction of eGFR loss based on a one-time htTKV measurement in an age-
dependent fashion [30]
PROPKD score Incorporates genetics, early onset of urological complications and hypertension, as well as gender into a
model predicting disease progression [31]
PROPKD score of >6 predicts reaching ESRD before 60 years of age [31]
Hypertension Hypertension has been linked to an increased risk of CKD progression [32]
Early onset of hypertension at <35 years old indicates earlier development of ESRD versus patients who are
normotensive until >35 years old [31, 33]
Gender Male ADPKD patients have been linked with decreased renal function and earlier onset of ESRD versus female
patients (52 versus 56 years old, respectively) [31, 33, 34]
Urological complications Onset of urological complications (flank pain, gross hematuria, cyst hemorrhages, cyst infections) before the
age of 35 is associated with rapid progression [31]
Age-adjusted eGFR loss If no sufficient eGFR measurements are available to evaluate the slope, the current eGFR can be used to esti-
mate whether a patient has undergone rapid progression in the past. For example, an old patient (e.g.,
>45 years) who has not lost kidney function will not be a rapid progressor whilst a young patient (e.g.,
25 years, CKD 2) showing a reduced eGFR due to ADPKD is very likely a rapid progressor [24]
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family history, their current age and health, their prognosis,
contraindications, potential adverse effects, as well as the
patients’ own personal desires/motivations for taking the
therapy.
Case 1
Case 1 was a 38-year-old male with a professional role in a large
corporation. He was an ex-smoker of 14 years and had a low
alcohol intake (<14 units/week). The patient’s mother and
younger brother both had a clinical diagnosis of ADPKD. The
mother had advanced to ESRD by the age of 61, while the
brother (aged 40) had not yet reached ESRD. Due to the patient’s
family history of ADPKD, the patient had undergone renal USS
screening at age 14, whereupon polycystic kidneys consistent
with a diagnosis of ADPKD were detected.
The patient presented with several comorbidities, including
hypertension, which had been diagnosed at the age of 26 and
was being controlled well using irbesartan. At the age of 15, the
patient experienced an episode of severe flank pain associated
with macrohaematuria. The patient’s extrarenal manifestations
of ADPKD included sigmoid diverticulosis and a small intracra-
nial aneurysm, which was managed conservatively. Echocar-
diography also revealed a concentric myocardial hypertrophy
but without signs of valvular dysfunction.
The patient’s renal function showed an eGFR [CKD
Epidemiology Collaboration (CKD-EPI)] of 41 mL/min/1.73 m2,
with a documented decline from 58 mL/min/1.73 m2 2.5 years
previous [eight creatinine values in between documenting the
slope; (CKD-3b)]. Genetic testing had not been performed, hence
a PROPKD score could not be calculated. A recent MRI had docu-
mented large kidneys with a htTKV of 1692 mL/m, putting the
patient into Mayo class 1E.
The family history of ADPKD and the patient’s early onset of
hypertension and urological complications, together with their
documented CKD-3b disease and Mayo class 1E at age 38, put
the patient at a high likelihood for rapid disease progression.
Based on the fact that few patients in CKD stage 3b had been
enrolled in TEMPO 3:4, the ERA-EDTA Working Groups on
Inherited Kidney Disorders and European Renal Best Practice
Fig. 1. Algorithm to assess indications for initiation of treatment in ADPKD. The diagram aims to define rapid progression, and thus allow the identification of patients
eligible for treatment. It is based on the assumption that GFR for age, or historical changes in GFR, provides more information on disease progression than changes in
TKV or risk prediction scores based on (ht)TKV or PKD gene mutation analysis in conjunction with clinical signs. Patients identified as showing ‘rapid progression’ or
‘likely rapid progression’ may be considered for treatment with tolvaptan. Patients with ‘possible rapid progression’ should be re-evaluated during follow-up visits.
Besides assessing the indication for treatment, contraindications to and special warnings for tolvaptan use in ADPKD should be considered. Notes to the decision algo-
rithm: (i) in our opinion, the indication ‘CKD stages 1–3 at initiation of treatment’ is not sufficiently specific as eGFR should be indexed for age. ADPKD patients with a
high eGFR for age are unlikely to show rapid disease progression. There is currently no published evidence for the effect of tolvaptan in patients below the age of 18 or
above the age of 50 years. (ii) The eGFR may vary over time in individual patients, especially when close to the normal range. To confidently define ‘rapid disease pro-
gression’, the rate of eGFR decline should be supported by multiple measurements that reliably indicate a rate of decline in eGFR. For this reason, this criterion should
also be defined more strictly when historical data are available for only a short period compared with when available for a longer period. (iii) When ‘evidence of rapid
disease progression’ is based on historical eGFR data, the decline in renal function should be due to ADPKD and not related to other diseases, medications or factors
that may contribute (reversibly or irreversibly) to a decline in renal function (e.g., diabetes mellitus, NSAIDs, calcineurin inhibitors, dehydration or contrast agents). (iv)
The criterion of decline in eGFR 5 mL/min/1.73 m2 in 1 year is adopted from the KDIGO CKD Guideline. (v) The criterion of decline in eGFR 2.5 mL/min/1.73 m2 per
year over a period of 5 years is comparable to class 1C patients in the Mayo classification of ADPKD. (vi) In young ADPKD patients with CKD stage 1, the observation of
‘no change in eGFR’ in general is not considered a sensitive marker of slow disease progression, as eGFR often remains fairly stable during a prolonged period of time,
whereas TKV increases steadily, suggesting disease progression. In such patients, changes in TKV and/or prediction models should be applied to assess historical or
predicted disease progression. (vii) The criterion of increase in TKV 5% per year is likely to be conservative. It is based on the threshold defining the Mayo class 1D
patients. This criterion has also been advocated by the Japanese regulatory authorities. The average rate of TKV growth in placebo-treated patients in the TEMPO 3:4
trial was 5.5% per year. (viii) The ellipsoid equation estimates TKV reliably when compared with classical volumetry. (ix) The Mayo classification of ADPKD is based on
htTKV indexed for age. It predicts that patients with class 1C, 1D and 1E have more rapid disease progression. A kidney length 16.5 cm, as assessed by ultrasound (or
MRI), can be used in patients <45 years to indicate a high likelihood of rapid disease progression. (x) The PROPKD score suggests that patients with a truncating PKD1
mutation and early onset of clinical signs (i.e., hypertension, macroscopic haematuria, cyst infection or flank pain before the age of 35 years) have rapid disease pro-
gression with start of renal replacement therapy at a relatively young age. (xi) Although there is significant variability in the age of reaching ESRD within families that
share the same mutation, clinical experience as well as observational studies have shown that a detailed family history can provide important information for risk pre-
diction. (Reproduced from Figure 3 of Gansevoort et al. [24].)
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position statement suggests that only patients up to CKD stage
3a should be commenced on tolvaptan [24]. This fact and its
implications were discussed with the patient. However, taking
into account that he had just reached this threshold, as well as
his young age, a decision was made to start treatment with tol-
vaptan, following counselling regarding possible impact on his
work as a manager of a large company. The patient did not
experience any major side effects and was able to plan his
workday and meetings around the polyuria without any signifi-
cant disruption.
Case 2
Case 2 was a 65-year-old male pensioner. Whilst the patient
had low alcohol consumption (<14 units/week) and a moderate
caffeine intake (1 cup/day), the patient was a heavy cigarette
smoker (46 pack years smoked). The patient had been diagnosed
with ADPKD during a routine clinical examination at the age of
55. The patient’s father died early without a diagnosis of ADPKD
and their mother did not suffer from ADPKD. The patient’s sis-
ter, however, had been diagnosed with ADPKD and underwent
unilateral nephrectomy at the age of 55. At the time of the
patient’s presentation, their sister had not reached ESRD at the
age of 64 years.
The patient’s comorbidities included hypertension, which
was diagnosed in later life and treated with candesartan and
bisoprolol, but with poor control. The patient had not experi-
enced any urological complications. The patient had suffered
various cardiovascular disorders, including hypertrophic
obstructive cardiomyopathy [which had been treated with an
automated implantable cardioverter defibrillator (AICD), sub-
valvular myectomy and mitral valve reconstruction], a recent
transient ischaemic attack and atrial fibrillation. Extrarenal
manifestations of ADPKD included sigmoid diverticulosis.
The patient’s renal function at presentation showed an eGFR
(CKD-EPI) of 32 mL/min/1.73 m2, with a documented decline from
49 mL/min/1.73 m2 3.5 years prior (seven creatinine values in
between documenting the slope; CKD-3b). Genetic testing had
not been performed, so a PROPKD score could not be calculated.
Also, due to the AICD, it had not been possible to perform an MRI;
however, sonographic measurements revealed an htTKV (ellip-
soid formula) that placed the patient into Mayo class 1D.
In this patient, tolvaptan was not recommended. Generally,
as the patient showed a significant loss of renal function and
fulfilled the criteria of Mayo class 1D, prescription of tolvaptan
would have been possible. However, there were no data regard-
ing the patient’s age group and little data regarding late CKD-3b.
In addition, the patient’s late onset of hypertension, the poor
control of hypertension, the patient’s other comorbidities and
their sister’s clinical history (not having reached ESRD despite
unilateral nephrectomy) indicated that these could have been
alternative explanations for the patient’s loss of kidney func-
tion. All these aspects were discussed with the patient and they
followed the recommendation not to commence tolvaptan
therapy.
Case 3
Case 3 was a 19-year-old, non-smoking, female high-school stu-
dent with low alcohol/caffeine intake. The patient had been
diagnosed with ADPKD in childhood due to bilaterally enlarged
cystic kidneys. The patient’s mother and grandmother both had
a history of ADPKD. At the time of presentation, the patient’s
mother was in CKD 4 at the age of 45. The patient’s grand-
mother died from ESRD at the age of 42 years.
At presentation, the patient had not experienced any comor-
bidities; the only known extrarenal manifestation was a single
liver cyst. An echocardiogram revealed no abnormalities. The
Fig. 2. MRI-based volumetry of polycystic kidneys using stereology and planimetry. In the clinical studies, the determination of TKV was performed mostly using ster-
eology or planimetry-based tracing (A and B). Whilst this approach yields the most accurate measurements, it is cumbersome and time-consuming and will conse-
quently not be generally available in the everyday clinical setting. Irazabal et al. showed that estimation of TKV using the ellipsoid equation, by measuring kidney
width and depth (D) in the axial and kidney length and (C) in both the sagittal and the coronal plane (with only the coronal plane being shown here), correlates well
with classical volumetry and is thus sufficient to guide clinical decision making outside the setting of clinical trials [30]. Images kindly provided by Thorsten Persigehl,
Department of Radiology, University of Cologne.)
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patient’s renal function showed an eGFR (CKD-EPI) of 140 mL/
min/1.73 m2 and MRI volumetry showed large kidneys with an
htTKV of 742 mL/m, putting the patient into Mayo class 1E.
Genetic testing was not performed, so a PROPKD score could not
be calculated.
Despite the lack of comorbidities and not being able to quan-
tify the patient’s eGFR loss, tolvaptan treatment was recom-
mended in this patient, primarily due to Mayo classification
(1E). Furthermore, despite the lack of genetics the family history
pointed towards a severe disease-causing mutation (such as a
truncating PKD1 mutation). Treatment was commenced at a
low dose after informing the patient that a safe method of con-
traception is required while on therapy. However, after several
weeks at low dose, the patient chose to discontinue treatment
due to difficulty incorporating polyuria into her everyday life.
This points to the fact that certain patient groups, including
very young patients that have not experienced any symptoms
of the disease, may have problems with adherence and require
a great deal of counselling and motivation. It was decided that
the patient would be reviewed on a yearly basis to re-discuss
treatment and commence tolvaptan once she felt she would be
able to incorporate this treatment in everyday life. Furthermore,
it was advised that a sufficient fluid intake (>3 L per day) should
be aimed for, even if not taking tolvaptan, as well as low salt
intake and an early initiation of antihypertensive medication
once hypertension is detected.
Case 4
Case 4 was a 29-year-old, fit and active male who worked as a
plumber. The patient had a known diagnosis of ADPKD,
detected following family screening (using renal USS) at the age
of 22 years.
The patient’s mother had ADPKD, reaching ESRD at the age
of 40. The patient’s maternal grandmother was also affected,
reaching ESRD at 50 years old. The patient’s maternal aunt also
had ADPKD and was in CKD 4 at the age of 50. The patient’s
comorbidities included hypertension, which was diagnosed at
the age of 22 following a nephrology outpatient clinic review
and treated with bisoprolol and perindopril with good control.
The patient’s renal function showed an eGFR [Modification of
Diet in Renal Disease (MDRD)] of 58 mL/min/1.73 m2, with a
documented decline from 64 mL/min/1.73 m2 14 months prior.
The patient had no major urological events. The investigation
of the mother’s younger siblings for potential live kidney donor
transplant allowed genetic testing to be performed, consistent
with the current UK Genetic Testing Network guidelines [40].
This identified a truncating mutation in PKD1 as the pathogenic
change leading to ADPKD in the family.
Recent imaging using renal USS had documented large kid-
neys (right renal length 22 cm; left renal length 23 cm) but MRI
imaging had not been performed. The patient’s PROPKD score
was 7 (out of a possible score of 9), suggesting that the patient
was at high risk of progression to ESRD—a PROPKD score of >6
predicts ESRD by the age of 60 [31]. Using Mayo criteria, the
patient’s estimated renal volume of>1000 mL/m would have
given a classification of 1E.
Treatment with tolvaptan was indicated in this patient due
to a risk of rapidly progressive disease, based on their family
history, age and risk factors. The effect of increased diuresis
was discussed in terms of its possible impact on his work as a
commercial plumber. Treatment was commenced and titrated
to full dose, with no major side effects. The patient was subse-
quently able to carry on with his work without disruption. This
case demonstrates the utility of the PROPKD score in person-
alizing the care of ADPKD patients, based on their risk for pro-
gression to ESRD.
Case 5
Case 5 was a 49-year-old, fit and active male who worked as a
chef. The patient had a known diagnosis of ADPKD, detected by
renal USS following documented hypertension at the age of
25 years and an episode of loin pain and haematuria.
There was no clear documented family history of ADPKD,
although his paternal grandfather had died from a subarach-
noid haemorrhage aged 70 years. His hypertension was treated
with lisinopril with good control. The patient’s renal function
showed an eGFR (MDRD) of 54 mL/min/1.73 m2, with a docu-
mented decline from 68 mL/min/1.73 m2 over the previous 5
years. The patient had no new major urological events or other
noted cause for a rapid loss of GFR. Genetic testing had not been
performed. Updated renal imaging using MRI documented a
TKV of 830 mL, a calculated htKTKV of 461 mL/m and Mayo clas-
sification 1B. Treatment with tolvaptan was discussed and initi-
ated. It was noteworthy that the patient worked in a hot
environment and was concerned over keeping up with fluid
intake. The tolvaptan treatment was tolerated for just 3 months
before complaints about polyuria and polydipsia necessitated a
break from treatment. This case demonstrates that despite low
prediction scores (via TKV) a rapid decline of GFR was sufficient
evidence for treatment with tolvaptan to be initiated. It also
demonstrated that work environments should be discussed in
detail prior to treatment and play an important role in the abil-
ity to maintain compliance with the medication.
Discussion
The use of tolvaptan has brought about a new era for patients
with ADPKD. As our selected cases have shown, there is need
for an up-to-date review of family history, medical history,
renal imaging and genetic findings in order to provide an
assessment of disease progression risk. The clinic setting to dis-
cuss tolvaptan now becomes an important opportunity to pro-
vide a holistic approach to all aspects of disease related to
ADPKD. It is our belief that such discussions are best suited to
being led by a multi-disciplinary team (e.g., including a nurse
specialist, renal pharmacist and a renal physician, comple-
mented by other specialties such as a radiologist and a pain spe-
cialist in specific cases) where progression of renal disease,
hypertension, renal pain and lifestyle factors can all be reas-
sessed. Historically, ADPKD patients were treated simply with
supportive measures. The advent of a new therapy allows us to
approach these patients in a new and more thoughtful way.
Real life cases, as presented here to provide treatment decisions
for tolvaptan, often lack data such as precise genetic diagnosis
and changes in renal volumes. Consequently, we suggest a
more pragmatic approach that considers the individual factors
as well as the patients’ lifestyle and comorbidities. Monitoring
of liver function is a requirement during tolvaptan therapy but
generally speaking, the drug appears to be safe and has few seri-
ous adverse effects [39].
Whilst there is a deservedly new emphasis on commencing
tolvaptan therapy in patients with ADPKD, other supportive
measures should not be neglected. It remains very important to
consider blood pressure control, low salt intake, sufficient fluid
intake, and avoidance of smoking, caffeine and non-steroidal
anti-inflammatory drugs. Indeed, results from the HALT-PKD
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trial emphasize the importance of blood pressure control in all
ADPKD patients [35], giving this factor particular attention
among healthcare professionals. Supportive measures should
be discussed with all patients independent from the question as
to whether they take tolvaptan. As to the drug itself careful
patient selection is essential to avoid treating patients that will
not benefit from this therapy, but also to minimize the eco-
nomic burden. We are convinced that with continued use of tol-
vaptan in patients with ADPKD, determination of its use will be
possible in a considered rational and pragmatic approach.
Appropriate guidance based upon published evidence will help
nephrologists gain experience with this important novel thera-
peutic option in ADPKD.
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